4SC AG

4SC provides Q1 2020 update

4SC AG: Conference call to be hosted on 21 April 2020 to present the Q1 report 2020

4SC AG: Bekanntmachung der Einberufung zur Hauptversammlung am 08.05.2020 in Planegg-Martinsried mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

4SC AG: FDA Accepts IND Application for MERKLIN 2 Study

4SC AG provides results for financial year 2019 and outlook

4SC to present at the World Congress of Cutaneous Lymphomas in Barcelona, Spain

4SC – Resminostat and RESMAIN Study Update

4SC AG: First Patient Enrolled in DONIMI Study Evaluating Domatinostat in the Neoadjuvant Setting in Melanoma

4SC AG: 3 upcoming conferences

4SC AG enters into avelumab supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for clinical combination study of domatinostat in Merkel cell carcinoma

4SC AG: Positive safety review of Phase Ib/II EMERGE study of domatinostat + avelumab in gastrointestinal cancer

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

4SC AG secures circa EUR 22.4 million from a capital increase

4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma

4SC provides Q3 business update and outlook

4SC and Netherlands Cancer Institute Collaborate on Clinical Evaluation of Domatinostat in the Neoadjuvant Setting in Melanoma

4SC AG: Conference call to be hosted on 17 October 2019 to present the Q3 Announcement 2019

4SC AG resolves to issue new shares; Santo and ATS undertake to subscribe / buy the new shares

4SC AG: First domatinostat combination data from Phase Ib/II SENSITIZE study presented at ESMO

4SC AG: Pivotal RESMAIN study of resminostat in CTCL: update at the EORTC CLTF meeting 2019 in Athens

4SC AG: Key resminostat scientific data to be presented at EORTC-CLTF meeting in Athens

4SC AG: Poster presentations at ESMO Congress 2019

4SC AG: 8 upcoming conferences

4SC AG receives milestone payment from Link Health – Link Health initiates Phase I clinical study of LH031 (4SC-205) in advanced solid malignancies or lymphoma

4SC AG provides Q2 and H1 2019 update